Will Muggia likes biotech. Muggia's Touchstone Mid-Cap Growth Fund is up an average of 14.9 percent annually over the last three years -- and even this year, it's up 1.8 percent. So what are the 4-star portfolio manager's picks?
Muggia likes Celgene, "one of the fastest-growing biotechnology companies in the world today. He expects the firm to have 40 percent earnings growth.
He praises Elan Pharmaceuticals for its auto-immune and Alzheimer's medicines. He says the latter illness has barely begun to be addressed medically, with plenty of potential left.
CNBC.com Web Exclusive:
(Not found on TV)
For CNBC.com readers, Muggia also recommends Chesapeake Energy.
Muggia personally owns both Celgene and Elan, and the stocks are the largest holdings in his fund.